Ultra-Processed Foods and Type 2 Diabetes: Results from the EPIC Cohort A major cohort study published in The Lancet Regional Health – Europe in September
Efsitora alfa: A New Hope for People with Type 1 Diabetes? A major international study published in September 2024 in The Lancet could redefine how
Short Sleep and Type 2 Diabetes Risk: Findings from 12.5 Years of Follow-up in the UK Biobank In March 2024, JAMA Network Open published a
Weight loss has long been associated with improved outcomes in diabetes management. While most research and public discourse focus on type 2 diabetes, weight management
In the age of biologics, kinase inhibitors, and personalized oncology, it may seem counterintuitive that a generic antihypertensive agent first approved in 1995 is reemerging
Rybelsus (semaglutide) works by mimicking a natural hormone in your body called GLP-1, which helps regulate blood sugar and digestion. When you take Rybelsus, it
Living with type 2 diabetes often means making important decisions about your treatment. Two popular medications, Jardiance and Glyxambi, are frequently prescribed to help manage
A central resource for analyzing the efficacy, mechanisms, and clinical use of SGLT2 inhibitors compared to other diabetes drug classes. Quick Links SGLT2 Inhibitors vs.
Managing type 2 diabetes can feel overwhelming, especially with so many treatment options available. Two of the most commonly prescribed medications are Invokana and Jardiance.
If you’re living with type 2 diabetes, choosing the right medication is a big decision. Two common options are Metformin and Glyxambi. Both are effective
© 2025 Wireless-Life Sciences Alliance. All rights reserved.